IDEAYA Biosciences, Inc.
IDYA
株式のランク
#4509
IDEAYA Biosciences, Inc. is a precision oncology company primarily dedicated to... IDEAYA Biosciences, Inc. is a precision oncology company primarily dedicated to identifying and advancing targeted therapies, particularly leveraging the concept of synthetic lethality. The firm aims to develop specific treatments for patient groups selected through molecular diagnostic methods. At the forefront of its clinical efforts are two investigational drugs. IDE397, a methionine adenosyltransferase 2a (MAT2A) blocking agent, is currently in early-stage (Phase I) trials for solid tumors exhibiting methylthioadenosine phosphorylase (MTAP) deletions. Its second primary candidate, IDE196, a protein kinase C (PKC) inhibitor, is progressing through Phase I/II studies, targeting genetically defined cancers characterized by GNAQ or GNA11 gene mutations. Beyond its clinical pipeline, IDEAYA's earlier-stage portfolio includes several synthetic lethality programs. These encompass a PARG inhibitor designed to address tumors with specific genetic or molecular biomarkers, Pol Theta inhibitors aimed at cancers presenting with BRCA or other homologous recombination deficiency (HRD) mutations, and WRN inhibitors for tumors demonstrating high microsatellite instability (MSI-H). The company also engages in significant collaborations. It has a joint research effort with Cancer Research UK and the University of Manchester, focusing on small molecule inhibitors of Poly (ADP-ribose) glycohydrolase. Furthermore, IDEAYA maintains a partnership with Pfizer Inc. for the clinical development and supply in Phase I/II trials across metastatic uveal melanoma, skin melanoma, and other solid tumors, alongside a strategic alliance with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was established in 2015 and operates from its headquarters in South San Francisco, California.
株価
$35.54
時価総額
$3.43B
変化（1日）
5.12%
変化（1年）
16.49%
国
US
取引 IDEAYA Biosciences, Inc. (IDYA)
カテゴリー
Healthcare
IDEAYA Biosciences, Inc.（IDYA）のP/E比率
October 2026 時点のP/E比率 TTM -17.64
IDEAYA Biosciences, Inc. の最新の財務報告および株価によると、現在の P/E (TTM) は -17.64 です。2023 年末時点での P/E は -18.12 でした。
IDEAYA Biosciences, Inc. の P/E 比率の履歴（2017 〜 2026）
各年末のP/E比率
| 年 | P/E比率 | 変化 |
|---|---|---|
| 2026 (TTM) | -17.64 | 130.53% |
| 2024 | -7.65 | -57.79% |
| 2023 | -18.12 | 31.86% |
| 2022 | -13.74 | -21.64% |
| 2021 | -17.53 | 63.45% |
| 2020 | -10.73 | 171.74% |
| 2019 | -3.95 | -14.92% |
| 2018 | -4.64 | -65.46% |
| 2017 | -13.43 | 0.00% |
類似企業や競合他社のP/E比率
| 企業 | P/E比率 | P/E比率の差 | 国 |
|---|---|---|---|
| 28.78 | -263.20% |
US
|
|
| -28.36 | 60.80% |
US
|
|
| -24.57 | 39.30% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | -271.98% |
NL
|
P/E比率の読み方
株価収益率（P/E Ratio）は、企業の株価と1株あたり利益の関係を示します。
低いが正のP/Eは、現在の評価額に対して高い利益を上げている企業を示し、割安と見なされる可能性があります。高い負の（0に近い）P/Eは、損失が大きいことを示します。
P/Eが30を超えるか、負である企業は一般に「成長株」と見なされ、投資家は将来的な成長または黒字化を期待しています。
10未満の正のP/Eを持つ企業は一般に「割安株」と見なされ、既に収益性が高いが成長の余地は小さいと見なされます。